Ani Pharmaceuticals (ANIP) EBITDA (2011 - 2026)

Ani Pharmaceuticals has disclosed EBITDA across 16 years of filings, most recently posting $40.5 million for Q2 2026.

• In Q2 2026, EBITDA rose 191.25% year-over-year to $40.5 million; the TTM figure through Jun 2026 stood at $150.4 million (up 889.89% YoY), while the FY2025 annual figure was $120.0 million, up 1402.92% from the prior year.
• EBITDA came in at $40.5 million for Q2 2026 at Ani Pharmaceuticals, up from $38.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $40.5 million in Q2 2026 to a low of -$20.5 million in Q3 2024.
• Average EBITDA over 5 years is $11.3 million, with a median of $11.1 million recorded in 2023.
• Year-over-year, EBITDA slumped 730.38% in 2022 and surged 894.13% in 2025.
• Over 5 years, EBITDA stood at $1.8 million in 2022, then surged by 269.56% to $6.7 million in 2023, then slumped by 165.09% to -$4.4 million in 2024, then surged by 894.13% to $34.8 million in 2025, then rose by 16.37% to $40.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $40.5 million in Q2 2026, $38.9 million in Q1 2026, and $34.8 million in Q4 2025.